This API Maker Stock Rises 66% in 1 Year: What Is Fuelling the Rally?
- September 10, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
CMP approximately Rs 9,438.50 (10 Sep 2026). 1-year return 66.03%. 52W range Rs 5,636.50 to Rs 9,615. Market cap Rs 2,51,737 Cr. Q1 FY27 PAT Rs 902 Cr vs Rs 545 Cr.
Quick Answer
Divi’s Laboratories, India’s largest pure-play API and custom synthesis company, is the API maker stock behind a return of approximately 66% in one year. The share climbed from a 52-week low of Rs 5,636.50 to a record Rs 9,615 as Q1 FY27 profit jumped around 66% and operating margin reached about 43%. Valuations are now rich at a PE near 86, and the price sits above most brokerage targets.
This API maker stock has turned Rs 1 lakh into roughly Rs 1.66 lakh in twelve months, and it did so as one of the largest companies on the exchange. A drug ingredient manufacturer worth about Rs 2.5 lakh crore delivered a 1-year return of 66.03% as of 10 September 2026, ranking 22nd in a screen of 101 large-cap and mid-cap NSE shares.
The company is Divi’s Laboratories Ltd (NSE: DIVISLAB), India’s largest pure-play maker of active pharmaceutical ingredients (APIs) and a major contract manufacturer for global drug companies. The Divi’s Laboratories share closed at approximately Rs 9,438.50 on 10 September 2026, down about 0.52% for the day, after touching a record Rs 9,615 in recent sessions. For an API maker stock of this size, a 66% move in a year is rare.
Click Here – Get Free Investment Predictions
How Much Has This API Maker Stock Returned Across Time Frames?
This API maker stock has returned 66.03% in one year and 57.46% in six months, which means most of the gain came in 2026. The Divi’s Laboratories share price moved from a 52-week low of Rs 5,636.50 to a high of Rs 9,615 on NSE, a swing of roughly 71% from bottom to top.
Here is how the API maker stock ranks across periods within the 101-stock screen:
| Period | Return (%) | Rank (out of 101) |
|---|---|---|
| 1 Month | 9.51% | 18 |
| 6 Months | 57.46% | 26 |
| 1 Year | 66.03% | 22 |
| 3 Years | 151.35% | 31 |
| 5 Years | 96.9% | 55 |
Returns are simple price changes and are not annualised. There was no stock split or bonus issue in the one-year window, so the gain is genuine price appreciation. The 5-year figure is weaker than the 3-year figure because the API maker stock went through a long slump after FY22, when profit fell from Rs 2,960 crore to Rs 1,600 crore by FY24 as pandemic-era demand faded.
The recent run has been consistent. The API maker stock gained about 14% in a single week around its Q1 FY27 results in early August, and a further leg higher took the Divi’s Laboratories share price to an all-time high of around Rs 8,915 on 26 August before it pushed past Rs 9,600 in September.
Why Did This API Maker Stock Rise 66% in 1 Year?
This API maker stock rose 66% because its custom synthesis business turned a corner, margins jumped to multi-year highs and investors started pricing in GLP-1 and peptide projects that begin commercial supply over the next 12 to 18 months. A shift of global drug supply away from China added a structural tailwind.
1. A Blockbuster Q1 FY27 Quarter
Divi’s Laboratories reported Q1 FY27 total revenue of approximately Rs 3,144 crore, up about 24% from Rs 2,529 crore a year earlier. Net profit jumped around 66% to Rs 902 crore, and EBITDA rose to Rs 1,319 crore from Rs 848 crore.
The operating margin expanded to 42.82% from 35.19%, the best quarterly margin in the five quarters shown below. Gross margin expanded by about 766 basis points to 68%, according to company disclosures reported in the media. For an API maker stock, that kind of margin jump signals a richer product mix rather than one-off pricing.
| Metric | Q1 FY27 (Jun 2026) | Q4 FY26 (Mar 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|---|
| Revenue | Rs 3,144 Cr | Rs 2,986 Cr | Rs 2,529 Cr | Up 24% |
| EBITDA | Rs 1,319 Cr | Rs 1,089 Cr | Rs 848 Cr | Up 56% |
| Operating Margin | 42.82% | 38.47% | 35.19% | Up 763 bps |
| Net Profit | Rs 902 Cr | Rs 751 Cr | Rs 545 Cr | Up 66% |
| EPS (Diluted) | Rs 33.95 | Rs 28.31 | Rs 20.49 | Up 66% |
The market rewarded the numbers immediately. The Divi’s Laboratories share price rallied about 5% on 3 August 2026 to a then record of Rs 8,464, and the company’s market value crossed Rs 2.25 lakh crore, overtaking several large auto and metal names.
2. Custom Synthesis Validation Batches Drove Growth
The custom synthesis segment, which makes up around 60% of revenue, grew about 45% year on year in Q1 FY27. Growth came from validation quantities supplied for three dedicated projects, backed by approximately Rs 1,400 crore of capitalised assets.
Management of this API maker stock said commercial supplies from these projects should begin in coming quarters after regulatory clearances. It also indicated that the elevated run rate should continue, since validation batches will keep flowing. That visibility is what turned this API maker stock from a steady compounder into a momentum name.
3. GLP-1 and Peptide Opportunity
GLP-1 drugs for diabetes and weight loss have become the fastest-growing class in global pharma, and they need large volumes of peptide ingredients and building blocks. This API maker stock has been adding peptide capacity and reported rising peptide-related order inflows.
Analysts expect GLP-1 peptide projects to start commercialising in CY27, and the company has multiple small-molecule and peptide projects lined up for launch over the next 12 to 18 months. The market treats this API maker stock as one of the few Indian listed ways to play that theme at scale.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
4. China Plus One and Contrast Media
Analysts cite a structural China plus one tailwind, supported by proposed US biosecurity rules that could push drug companies to diversify supply away from Chinese vendors. As the largest pure-play API and contract manufacturer in India, this API maker stock is a natural beneficiary, and no other API maker stock in the country matches its scale.
Contrast media is a second new leg. The company began supplies to two new customers and expects to sign a multiyear contract in this segment within three to four months. Generic APIs grew about 6% and nutraceuticals rose around 19% in the quarter, so the older businesses are also holding up.
5. Capacity Expansion Without Debt
Capital expenditure rose to Rs 2,520 crore in FY26 from Rs 1,438 crore in FY25, funding peptides, key starting materials and nutraceuticals. Even so, the API maker stock remains debt free, with a debt to equity ratio of 0.00, and operating cash flow climbed to Rs 2,738 crore in FY26.
Funding growth from internal cash is a key comfort factor for investors in this API maker stock. It removes refinancing risk and keeps the dividend of Rs 30 per share intact.
Five-Year Financial Trend of This API Maker Stock
Annual numbers for this API maker stock show a clear recovery. After falling in FY23 and FY24, revenue rose to Rs 11,067 crore in FY26 and net profit to Rs 2,568 crore, the highest since FY22.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue (Rs Cr) | 9,074 | 8,112 | 8,184 | 9,712 | 11,067 |
| EBITDA (Rs Cr) | 3,996 | 2,712 | 2,544 | 3,320 | 3,874 |
| Net Profit (Rs Cr) | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 |
| Operating Margin | 44.61% | 34.94% | 32.44% | 35.48% | 36.70% |
| EPS (Rs) | 111.52 | 68.69 | 60.27 | 82.53 | 96.75 |
FY26 profit is still below the FY22 peak, but trailing EPS has already climbed to approximately Rs 110.18 after the strong June quarter. If the Q1 FY27 margin holds, FY27 could be the first year that this API maker stock beats its pandemic-era earnings.
Who Owns This API Maker Stock?
Promoters hold a steady 51.88% of this API maker stock, almost unchanged over the last five quarters. Foreign institutions hold about 20.2% and domestic institutions around 19.38%, while public holding has drifted down from 9.32% to 8.54%.
| Shareholder | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 51.89% | 51.89% | 51.88% | 51.88% | 51.88% |
| FIIs | 19.74% | 19.39% | 20.08% | 20.29% | 20.20% |
| DIIs | 19.05% | 19.76% | 19.28% | 19.22% | 19.38% |
| Public | 9.32% | 8.96% | 8.76% | 8.61% | 8.54% |
The Government of Singapore raised its stake to 3.64% from 2.64% a year ago, while SBI Mutual Fund and LIC trimmed holdings slightly. Institutional ownership of nearly 40% keeps the API maker stock heavily tracked, and its weight in healthcare and Nifty Next 50 index funds adds steady passive demand.
What Are the Risks for This API Maker Stock?
The biggest risk for this API maker stock is valuation. At a trailing PE of approximately 86 against an industry PE of around 38, and a price to book of about 15, the market is already paying for several years of growth.
Execution risk: Custom synthesis revenue at this API maker stock is lumpy. The Q1 FY27 jump was driven by validation batches, and if regulatory clearances or commercial orders slip, quarterly numbers can swing sharply.
Margin pressure: In Q4 FY26, EBITDA margin fell about 100 basis points on raw material inflation linked to crude oil and ammonia. A reversal of the current favourable currency trend would also hurt, since most revenue comes from exports.
Customer concentration: A handful of large innovator clients drive custom synthesis at this API maker stock. Losing or delaying a single major molecule could hit growth expectations for the API maker stock.
Generic API pricing: Management has flagged pricing pressure in generics. If competition from Chinese suppliers intensifies, the older business of the API maker stock could drag on the blended margin.
Crowded trade: After a 66% rally in this API maker stock, several domestic brokerages now rate the shares hold, reduce or sell. Any disappointment could trigger profit booking in the Divi’s Laboratories share price.
Download the Univest iOS App or Univest Android App to track the Divi’s Laboratories share price live
Divi’s Laboratories Share: Analyst View
Analyst views on this API maker stock are sharply split. Bulls point to a 20% to 22% revenue CAGR from FY26 to FY29, while bears argue the current price already reflects that growth.
Divi’s Laboratories Share Price Target
The highest verified Divi’s Laboratories share price target is Rs 10,200 from a foreign brokerage, which named the company a top pick in late August 2026. A domestic brokerage set a Divi’s Laboratories share price target of Rs 9,799 with a buy rating, valuing the business at 40 times June 2028 EBITDA.
| Brokerage | Rating | Target (Rs) | Implied Move vs Rs 9,438.50 |
|---|---|---|---|
| A foreign brokerage | Buy (top pick) | 10,200 | Up about 8% |
| A domestic brokerage | Buy | 9,799 | Up about 4% |
| A domestic brokerage | Reduce | 8,355 | Down about 11% |
| A domestic brokerage | Hold | 7,959 | Down about 16% |
| A domestic brokerage | Sell | 6,500 | Down about 31% |
The spread for this API maker stock is wide, ranging from roughly 31% below to about 8% above the current price. With the shares trading close to the top of that range, the average Divi’s Laboratories share price target now sits below the market price.
On technical levels, Rs 9,615 is the immediate resistance marked by the 52-week high, while the Q1 results breakout zone around Rs 8,400 to Rs 8,500 is the first major support. A close above the record high would signal fresh momentum, while a break below the breakout zone would suggest the rally is cooling.
Conclusion
This API maker stock earned its 66% one-year gain through real earnings delivery, not hype. Q1 FY27 profit rose around 66%, margins hit about 43%, the balance sheet is debt free and GLP-1, peptide and contrast media projects give the business a multi-year runway.
The catch is price. At around 86 times trailing earnings and above most brokerage targets, the Divi’s Laboratories share price leaves little room for a missed quarter. Investors tracking this API maker stock should watch commercial supply timelines for the custom synthesis projects, peptide order conversion and margin stability over the next two quarters.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which API maker stock rose 66% in 1 year?
Ans. Divi’s Laboratories (NSE: DIVISLAB) is the API maker stock that gained approximately 66.03% over one year as of 10 September 2026. It ranked 22nd among 101 large-cap and mid-cap NSE stocks screened for this analysis.
Why did Divi’s Laboratories share price rise in the last year?
Ans. The Divi’s Laboratories share price rose on strong custom synthesis growth, a Q1 FY27 profit jump of around 66% and an operating margin of about 43%. Investors are also pricing in GLP-1 and peptide projects and China plus one supply shifts.
What were Divi’s Laboratories Q1 FY27 results?
Ans. Divi’s Laboratories reported Q1 FY27 total revenue of approximately Rs 3,144 crore, up about 24% year on year. Net profit rose to Rs 902 crore from Rs 545 crore, and EBITDA climbed to Rs 1,319 crore from Rs 848 crore.
Is this API maker stock overvalued?
Ans. On trailing numbers the valuation is rich, with a PE of approximately 86 against an industry PE of around 38. The market is paying for future custom synthesis and peptide growth, so any delay in commercial supplies could lead to a correction.
What is the 52-week high and low of Divi’s Laboratories?
Ans. Divi’s Laboratories has a 52-week high of Rs 9,615 and a 52-week low of Rs 5,636.50 on NSE. The share closed at approximately Rs 9,438.50 on 10 September 2026, about 2% below its record high.
Does Divi’s Laboratories have any debt?
Ans. No, Divi’s Laboratories is effectively debt free, with a debt to equity ratio of 0.00. It funded Rs 2,520 crore of FY26 capex from internal cash and generated Rs 2,738 crore of operating cash flow.
What is the Divi’s Laboratories share price target?
Ans. Verified brokerage targets range from Rs 6,500 to Rs 10,200. A foreign brokerage has the highest target of Rs 10,200, while a domestic brokerage with a buy rating sees Rs 9,799. Targets are estimates, not assurances.
Should I invest in an API maker stock after a 66% rally?
Ans. A 66% move means much of the good news is already priced in, so fresh buyers face valuation and volatility risk. Staggered buying, a clear stop loss and tracking of quarterly execution are sensible, and consulting a SEBI-registered advisor is recommended.
